Bristol Myers Squibb’s CAR‑T therapy Breyanzi received FDA approval for third‑line treatment of marginal zone lymphoma, making it the first CAR‑T approved for this rare, indolent non‑Hodgkin lymphoma subtype. The authorization expands Breyanzi’s label and broadens CAR‑T use into a new lymphoma population. Regulatory clearance reflects clinical trial evidence of durable responses in later‑line patients. For context: marginal zone lymphoma typically follows an indolent course but can be refractory to standard therapies, creating a niche for cellular therapies in relapsed settings.